Document:

Exhibit
10.2

 

Research
Agreement 

 

This
Research Agreement (the “Agreement”), is made and entered into on May 2, 2018, between Canna Powder Ltd, of
20 Raul Wallenberg, Tel -Aviv, Israel (the “Company”) and Yissum Research Development Company of The Hebrew
University of Jerusalem, Ltd. with its registered address at Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390,
Israel (“Yissum”).

 

	WHEREAS:
    	Yissum
    and the Company have executed a license agreement effective May 2, 2018 (the “License Agreement”); and
	 	 
	WHEREAS:	the
    Company wishes to sponsor research in the laboratory of the Researcher for the further development of the Licensed Technology;
    and
	 	 
	WHEREAS:
    	all
    capitalized terms in this Agreement shall have the meaning ascribed to them in the License Agreement unless specifically indicated
    otherwise herein.

 

NOW
the Company and Yissum agree to all of the following terms and conditions:

 

	1.	The
    Research:

 

	 	1.1	Yissum,
    through the Faculty of Science of The Hebrew University of Jerusalem (“HUJI” or the “University”),
    shall perform certain research during the Research Period (as defined below), employing the services of the Researcher (as
    defined below), all strictly in accordance with the details, objectives and specifications of the protocol attached hereto
    as Appendix A (and as may be amended from time to time by the Parties) (the “Research” and
    the “Research Protocol”, respectively). 
	 	 	 
	 	1.2	Yissum
    is aware that parts of the Research may be performed by employees of the Company under the supervision of the Researcher outside
    HUJI facilities. In the event that the Company desires one or more of its employees to perform any Research in any HUJI facility,
    it may do so only after it has obtained the necessary HUJI approvals. Yissum is free to cause the performance of the Research
    as provided for herein, and that the Researchers are free to perform the Research as provided for herein; and Yissum warrants
    and represents that there are no contracts and/or restrictive covenants preventing the performance thereof and that it, and
    the Researchers, will not enter into any conflicting contracts and/or restrictive covenants during the Research Period. 
	 	 	 
	 	1.3	For
    the avoidance of doubt, nothing herein shall prevent Yissum or the University or the Researcher from obtaining any finance
    or grants from other entities for research regarding the Licensed Technology, provided that such entities shall not be granted
    rights in the Research or Research Results prejudicial to the rights granted to the Company in this Agreement. The results
    of any such research financed by other entities shall not form part of the Licensed Technology and shall not be subject to
    the License hereunder.
	 	 	 
	 	1.4	Nothing
    contained in this Agreement shall be construed as a warranty on the part of Yissum that any results or inventions will be
    achieved by the Research, or that the results of the Research, if any, are or will be commercially exploitable. Yissum make
    no warranties whatsoever as the commercial or scientific value of the results of the Research Results.

 

	2.	Time
    Schedule: 

 

	 	2.1	Start
    Date: The start date shall be the date following the actual written receipt by Yissum of an applicable permit to perform
    the Research issued by the Israeli Ministry of Health. Yissum shall promptly notify Company following the receipt of such
    approval.
	 	 	 
	 	2.2	Research
    Completion Date: December 31, 2018 (the “Completion Date”) and upon the Researchers’ presentation
    to the Company of the Scientific Report (as defined below), provided that the Company had paid the Research Fee according
    to the schedule set forth herein, (the period extending from the Start Date to the Completion Date being referred to as the
    “Research Period”). The Company shall be entitled to extend the Research Period for a period of up to an
    additional year upon mutual agreement regarding additional payment.

 

    	1

    	 

    

 

	3.	The
    Researcher:

 

	 	3.1	The
    Research will be performed by, or under the control and supervision of, Professor Shlomo Magdassi (the “Researcher”).
    In the event that the Researcher, for any reason whatsoever, shall be unable to conduct the Research, or shall cease to be
    available for the performance of the undertakings set forth in this Agreement, Yissum shall use its best efforts to appoint,
    within 30 (thirty) days, a successor researcher whose identity shall be approved in advance by the Company (the “Successor
    Researcher”). Upon the Successor Researcher’s appointment, the Successor Researcher shall be deemed to be
    a Researcher for all purposes herein. Should the Parties not be able to agree on the identity of a Successor Researcher, notwithstanding
    their best efforts to do so, the Company shall have the right to terminate the Research and will bear no liability for such
    termination, provided that (i) no monies paid to Yissum for the Research pursuant to Section 5.1, below, will be refunded
    by Yissum to the Company, and (ii) the Company shall be responsible for the payment of any accrued fees and expenses due to
    Yissum based on work duly performed up to the date of termination and those irrevocable commitments entered into by Yissum
    prior to having received the Company’s written notice of termination.
	 	 	 
	 	3.2	In
    the performance of the Research, Yissum and the Researcher shall cooperate with, and as necessary, reach decisions with the
    agreement of the Company’s CEO and/or any official appointed by the Company for such purpose.
	 	 	 
	 	3.3	The
    Researcher shall perform the Research to the best of his abilities, in a diligent, trustworthy, professional and efficient
    manner, and with the due care and diligence as required by the best practice in the field of academic research. The Researcher
    shall comply with: (i) with all applicable laws and regulations, as may be amended from time to time; and (ii) with all applicable
    standards, regulations or guidelines for good academic research practice. 

 

	4.	The
    Scientific Report: The Researcher shall maintain complete and accurate written records, accounts, notes, reports and
    data of the Research. Within thirty (30) days of the end of the Research Period, the Researcher shall submit to the Company,
    a written scientific report, in accordance with professional academic research standards detailing the results of the Research,
    in a form proposed by the Company and agreed upon by the Researcher (such agreement not to be unreasonably refused) (the “Scientific
    Report”). The Company acknowledges that no financial report will be given by Yissum. In addition to the aforesaid,
    the Researcher shall meet once a calendar quarter during regular working hours with a representative of the Company and in
    accordance with the Researcher’s schedule, to orally inform the Company as to the progress of the Research. Without
    derogating from the generality of the foregoing, the Researcher shall submit to the Company a written report, on a quarterly
    basis, detailing the progress of the Research in a format reasonably acceptable to the Company. Further, the Researchers shall
    assist the Company in providing any report or information as may be required or requested by the Company in order for the
    Company to meet its reporting obligations to the IIA.

 

	5.	The
    Research Fee:

 

	 	5.1	The
    Company shall pay Yissum ten thousand US Dollars (US$10,000) per month, inclusive of overhead (the “Research Fee”)
    in consideration for the performance of the Research.
	 	 	 
	 	5.2	The
    Research Fee shall be paid by the Company to Yissum on a monthly basis until the completion of the Research (estimated date
    December 31st 2018).
	 	 	 
	 	5.3	Value
    Added Tax (VAT), as applicable, shall be added to all payments hereunder, and payments to Yissum shall be made against a duly
    issued VAT invoice within 30 (thirty) days of the Company’s receipt of the respective invoice. 
	 	 	 
	 	 	In
    the event that the Company fails to pay an invoiced amount in a timely manner, Yissum shall be entitled to charge the Company
    an additional fee equal to an annual interest rate of Prime plus 2% of such amount.

 

    	2

    	 

    

 

	6.	Intellectual
    Property: The Research Results shall be exclusively owned by Yissum and shall be automatically included in the Licensed
    Technology.
	 	
	7.	Use
    of Names: A Party shall not make any use of any kind of the name of the other Party, and, in the case of the Company,
    the names of the Researchers or the Hebrew University, without the prior written consent of the other Party, which shall not
    be unreasonably withheld. 
	 	 
	8.	Relationship
    of the Parties: Nothing in this Agreement shall in any way be construed to constitute there being a relationship of
    agent, employer-employee, or representative, between the Company on the one hand, and the Researcher and Yissum on the other
    hand. The relationship of the Company, on one hand, and the Researcher and Yissum, on the other hand, shall be that of independent
    contractors.
	 	 
	9.	Dispute
    Resolution: In all cases in which a dispute shall arise between the Company and Yissum regarding the Research, the
    dispute shall be resolved in accordance with the provisions of Section 16 of the License Agreement.
	 	 
	10.	Authorized
    Signatories: Signature by two authorized representatives of Yissum on this Agreement shall constitute Yissum’s
    approval and agreement to all that is written herein. The Company warrants that the persons signing this Agreement are authorized
    to bind the Company.
	 	 
	11.	Liability
    and Indemnification:

 

	 	11.1	Yissum,
    its ultimate owners, affiliates, officers, directors, employees, agents and contractors shall not be liable for any and all
    claims, actions, demands, losses, damages, costs and expenses (including without limitation legal fees) made or brought by
    third parties arising from or in connection with this Agreement (collectively, a “Claim”).
	 	 	 
	 	11.2	The
    Company’s indemnification obligations with respect to a Claim shall be in accordance with the provisions of Section
    14 of the License Agreement. 

 

	12.	Termination:

 

	 	12.1	Unless
    earlier terminated in accordance with the provisions of this Agreement, this Agreement shall end at upon the Company’s
    receipt of the Scientific Report, in accordance with the provisions of Section 4, above, and full payment of the Research
    Fee, in accordance with the provisions of Section 5, above.
	 	 	 
	 	12.2	Each
    Party shall be entitled to terminate this Agreement in the event of a breach by the other Party of its obligations under this
    Agreement, including, but not limited to, the Company’s payment of the Research Fee and/or Yissum’s or the Researcher’s
    failure to perform the Research, where such breach is not remedied by the breaching Party within 30 (thirty) days of receipt
    of written notice from the non-breaching Party.
	 	 	 
	 	12.3	Without
    derogating from the aforesaid, the Company shall be entitled to terminate this Agreement, for any reason at its sole discretion,
    upon sixty (60) days prior written notice to Yissum.
	 	 	 
	 	12.4	If
    the Agreement is terminated prior to the end of the Research Period, all amounts paid by the Company under this Agreement
    up to the date of termination shall be considered as non-refundable. In addition, should the Company have terminated this
    Agreement in accordance with Section 12.3, above, it shall continue to be liable for any irrevocable financial commitments
    made by Yissum or the Researcher in accordance with the Research Plan.
	 	 	 
	 	12.5	Sections
    3.1 (The Researcher), 4 (the Scientific Report), 5 (The Consideration), 6 (Intellectual Property), 8 (Relationship of the
    Parties), 9 (Dispute Resolution), 12 (Termination), 13 (Incorporation) and 14 (Governing Law) shall survive termination of
    this Agreement for any reason.

 

	13.	Incorporation:
    Sections 12 (Confidentiality), 13 (Publication Rights), and 17 (Miscellaneous) of the License Agreement shall be incorporated
    into and form part of this Agreement, mutatis mutandis.

 

    	3

    	 

    

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

 

	 	 	 
	Canna
    Powder Ltd. 	 	Yissum
    Research Development Company of The Hebrew University of Jerusalem Ltd.
	 	 	 		 
	By:	      	 	By:	          
	Title:
    	 	 	Title:	 

 

I
the undersigned, Professor Shlomo Magdassi, hereby declares and confirms that I have read and understood the Research Agreement,
I agree to be appointed as the Researcher on behalf of Yissum, and I undertake to comply with all the conditions, provisions,
instructions and stipulations of the Research Agreement.

 

	 	 	 
	Professor
    Shlomo Magdassi	 	Date

 

    	4

    	 

    

 

Appendix
A

 

Research
Program

 

Research
plan 

Cannabis
oil powders 

 

The
aim of the research is to develop cannabis oil powder as a raw material for pharmaceutical products, mainly fast dissolving tablets
and Powder inhalation. The research is a continuation of the feasibility study that was performed during the last months. 

 

The
main activities which will take place from May 1st to Dec 31, 2018, will be:

 

	 	●	Formation
    of cannabis oil powder according to the specific applications, (oral delivery/ inhalation), will be performed with a suitable
    / DFA approved ingredients. 
	 	 	 
	 	●	Scale
    up of the production process up to 1L of starting emulsion will be developed.
	 	 	 
	 	●	Filing
    of a patent application.
	 	 	 
	 	●	Developing
    preliminary formulations for two products: 
	 	 	 
	 	●	A
    soluble tablet under the tongue
	 	 	 
	 	●	Powder
    for use in inhalator for the lungs 

 

*The
research plan may change according to the developments in the research and business needs. 

 

    	5Exhibit
10.3

 

LICENSE
AGREEMENT

 

This
License Agreement (“Agreement”) is made in Jerusalem this 2nd day of May 2018 (the “Effective
Date”), by and between:

 

YISSUM
RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram,
Jerusalem 91390, Israel (“Yissum”), of the first part; and CANNA POWDER LTD, of 20 Raul Wallenberg,
Tel Aviv, Israel (the “Company”), of the second part; (each of Yissum and the Company, a “Party”,
and collectively the “Parties”)

 

	WHEREAS:	in
    the course of research conducted by Prof. Magdassi (the “Researcher”), at the University (as defined in
    Section 1 below), the Researcher developed technology of Powder Formulation of Cannaboid Oil as more fully described in the
    patent application[s] [and patent[s]] listed in Appendix A (collectively, the “Existing Patents); and
	 	 
	WHEREAS:	pursuant
    to the regulations of the University, the rights and title to all inventions, know-how and the results of research created
    by scientists of the University vest solely with Yissum, including the technology developed by the Researcher as aforesaid;
    and
	 	 
	WHEREAS:	the
    Company has represented to Yissum that (i) the Company is experienced, or engages the appropriate experts who have experience
    in the development of products in the Field similar to those to be based on the inventions and the results of research that
    are the subject of this Agreement; and (ii) either by itself or through third parties, it has the financial capacity and the
    strategic commitment to facilitate the development, production, marketing, sale and distribution of such products; and
	 	 
	WHEREAS:	The
    Company wishes to obtain a license from Yissum for the development and commercialization, in the Field, of the inventions
    covered by the Existing Patents, as well as the results of the research conducted under this Agreement; and
	 	 
	WHEREAS:	Yissum
    agrees to grant the Company such a license, all in accordance with the terms and conditions of this Agreement.

 

NOW
THEREFORE THE PARTIES DO HEREBY AGREE AS FOLLOWS:

 

	1.	Interpretation
    and Definitions

 

	1.1.	The
    preamble and appendices to this Agreement constitute an integral part hereof and shall be read jointly with its terms and
    conditions.
	 	 
	1.2.	In
    this Agreement, unless otherwise required or indicated by the context, the singular shall include the plural and vice-versa,
    the masculine gender shall include the female gender, “including” or “includes” shall mean including,
    without limiting the generality of any description preceding such terms and the use of the term “or” shall mean
    “and/or” and any reference to the term “sale” shall include the sale, lease, rental, or other disposal
    of any Product.
	 	 
	1.3.	The
    headings of the Sections in this Agreement are for the sake of convenience only and shall not serve in the interpretation
    of the Agreement.

 

    	1

    	 

    

 

	1.4.	In
    this Agreement, the following capitalized terms shall have the meanings appearing alongside them, unless provided otherwise:

 

	 	1.4.1.	“Affiliate”
    shall mean any person, organization or other legal entity which controls, or is controlled by, or is under common control
    with, the Company. “Control” shall mean the holding of more than fifty percent (50%) of (i) the equity,
    or (ii) the voting rights, or (iii) the right to elect or appoint directors.
	 	 	 
	 	1.4.2.	“Development
    Plan” shall mean the written plan and timetable, a copy of which is attached to this Agreement as Appendix C,
    for the development and the commercialization of Products, including specific development milestones, prepared by the Company
    and approved by Yissum pursuant to Section 5.1 below.
	 	 	 
	 	1.4.3.	“Development
    Results” shall mean the results of activities carried out by the Company or by third parties (other than the Researcher
    and his/her team or any other University employee) at the direction of the Company pursuant to the Development Plan or otherwise
    in fulfillment of the Company’s obligations hereunder (including its development obligations under Section 5 below),
    including any invention, patent or patent application, product, material, method, discovery, composition, process, technique,
    know-how, data, information or other result which do not form part of the Licensed Technology, and further including any governmental
    or regulatory filing submitted, or approval, license, registration, or authorization obtained, by the Company, an Affiliate
    or Sublicensee in respect of the Products, as well as any other information, data, material, results, devices and know-how
    arising from the performance of the Development Plan.
	 	 	 
	 	1.4.4.	“Field”
    shall mean Powder Formulation of Cannaboid Oil.
	 	 	 
	 	1.4.5.	“First
    Commercial Sale” shall mean the first sale of a Product by the Company, an Affiliate or a Sublicensee after the
    receipt of any required regulatory approval to market and sell such Product. Notwithstanding the foregoing and for the avoidance
    of doubt, sales of Products for the purposes of clinical trials or other testing prior to a First Commercial Sale shall entitle
    Yissum to payment of consideration in accordance with Sections.‎7.1 (Royalties) and‎7.2. (Sublicense Fee) of this
    Agreement, but shall not be considered a First Commercial Sale.
	 	 	 
	 	1.4.6.	“Know-How”
    shall mean any non-public, proprietary, tangible or intangible information, techniques, technology, practices, trade secrets,
    inventions, methods, processes, knowledge, ancillary materials, results or devices (whether patentable or not) developed by
    the Researcher, prior to the execution of this Agreement, solely and directly related to the subject matter claimed in the
    Existing Patents, and belonging to Yissum and described generally in Appendix A.
	 	 	 
	 	1.4.7.	“License”
    shall have the meaning set forth in Section 3.1 below.
	 	 	 
	 	1.4.8.	“Licensed
    Patents” shall mean (i) the Existing Patents, and any patent application that claims priority therefrom; as well
    as (ii) all divisions, continuations, continuations-in-part, re-examinations, reissues, renewals, registrations, confirmations,
    substitutions, or extensions, including European Supplementary Protection Certificates (“SPCs”) (within the meaning
    of such term under Council Regulation (EU) No. 1768/92), and/or any other similar statutory protection, and any provisional
    applications, national, regional, PCT or similar applications and any and all patents issuing from, and patentable inventions,
    methods, processes, and other subject matter disclosed or claimed in, any or all of the foregoing.
	 	 	 
	 	1.4.9.	“Licensed
    Technology” shall mean the Know-How, the Research Results and the Licensed Patents.
	 	 	 
	 	1.4.10.	“Net
    Sales” shall mean:

 

	 	(a)	the
    gross sales price invoiced for sales of Products by the Company, an Affiliate or Sublicensee to a third party; or
	 	 	 
	 	(b)	the
    fair market value of non-monetary consideration received in connection with such sales; after deduction of: (i) commercially
    reasonable discounts and return credits to the extent actually taken by third parties; and (ii) sales taxes, including VAT
    paid by customers for transfer in full to applicable tax authorities; provided that such deductions shall be directly related
    to the sale of Products that were awarded within the regular running of the business of the Company, Affiliate or Sublicensee.
    For the sake of clarity, any payment or rebate received by the Company, an Affiliate or Sublicensee from any governmental
    agency directly in relation to the sales shall be considered as Net Sales.

 

    	2

    	 

    

 

In
the event of sales of Products made through a distributor, or marketing agent where the transfer to the distributor or marketing
agent was made for a price certain without the Company, Affiliate or Sublicensee being entitled to any further compensation for
such transfer based upon the price at which the distributor or marketing agent sells Products to a third party, the sales made
by such distributor or marketing agent to a third party shall not be deemed gross sales for the purposes of this Agreement. Rather,
the gross sales shall be the amounts invoiced for Products transferred to such distributor or marketing agent by the Company,
an Affiliate or Sublicensee.

 

In
the event of sales or deductions not made at “arms-length”, then for the purpose of calculation of Royalties (as defined
below) to Yissum, Net Sales shall be calculated in accordance with arms-length prices for sale of Products to an independent third-party
purchaser and arms-length deductions, to be determined by the current market conditions, or in the absence of such conditions,
according to the assessment of an independent appraiser to be selected by the Parties.

 

	 	1.4.11.	“Product”
    shall mean any product, system, device, material, method, process or service, the development, manufacture, provision or sale
    of which, in whole or in part (i) uses, exploits, comprises, contains, improves upon or incorporates the Licensed Technology
    or the Development Results or any part thereof, or is otherwise covered thereby, or falls within the scope thereof, in whole
    or in part, or uses the Licensed Technology or the Development Results as a basis for subsequent modifications; or (ii) but
    for the License (as defined below) would infringe any claim of a Licensed Patent.
	 	 	 
	 	1.4.12.	“Representatives”
    shall mean employees, researchers, officers, agents, subcontractors, consultants, and/or any other person or entity acting
    on a Party’s behalf.
	 	 	 
	 	1.4.13.	“Researcher”
    shall mean Prof. Prof. Shlomo Magdassi or such other person as determined and appointed from time to time by Yissum to supervise
    and to perform the Research, if applicable.
	 	 	 
	 	1.4.14.	“Research
    Results” shall mean any inventions, products, materials, compounds, compositions, substances, methods, processes,
    techniques, know-how, data, information, discoveries and other results of whatsoever nature, discovered or occurring in the
    course of, or arising from, the performance of the Research, including any patent applications and patents (which shall be
    added to the list of Licensed Patents set forth on Appendix A), information, material, results, devices or know-how
    arising therefrom.
	 	 	 
	 	1.4.15.	“Royalties”
    shall have the meaning set forth in Section 7.3 below.
	 	 	 
	 	1.4.16.	“Subcontracting
    Agreement” shall mean (i) a bona fide subcontracting agreement with a subcontractor in which the Company must grant
    the subcontractor the right to make use of the Licensed Technology on behalf of the Company, and for which use the Company
    is required to pay or otherwise compensate the subcontractor, including, but not limited to, manufacturing or developing any
    of the Products (or part thereof); or (ii) a bona fide arms-length research agreement, pursuant to which an academic or research
    institution is engaged for the purpose of performing research, on the Company’s behalf, for the development of any of
    the Products (or part thereof); provided that in no event shall the consideration (if any) therefor comprise any Products;
    and further provided that such subcontracting agreement in (i) and (ii) above shall contain terms substantially as protective
    in relation to the Licensed Technology, as the terms of this Agreement; and the term “Subcontractor” shall
    be construed accordingly.
	 	 	 
	 	1.4.17.	“Sublicense”
    shall mean any grant by the Company or its Affiliates of any of the rights granted under this Agreement or any part thereof;
    including the right to develop, manufacture, market, sell or distribute the Licensed Technology or any Product, for which
    grant the recipient of the Sublicense is required to pay the grantor of the Sublicense (or the grantor’s related entity),
    excluding a Subcontracting Agreement.

 

    	3

    	 

    

 

	 	1.4.18.	“Sublicense
    Consideration” shall mean any proceeds or consideration or benefit of any kind whatsoever, whether monetary or otherwise,
    that the Company or an Affiliate may receive from a Sublicensee as a direct or indirect result of the grant of a Sublicense
    or an option for a Sublicense and/or pursuant thereto, including, without limitation, any amounts that are part of the consideration
    to be received by the Company or an Affiliate but which are withheld at source by the Sublicensee on account of tax owed by
    the Company or an Affiliate, except amounts received by the Company which constitute royalties based on sales by Sublicensees
    in respect of which the Company is required to pay Royalties to Yissum.
	 	 	 
	 	1.4.19.	“Sublicense
    Fees” shall have the meaning set forth in Section 7.6 below.
	 	 	 
	 	1.4.20.	“Sublicensee”
    shall mean any third party to whom the Company or an Affiliate shall grant a Sublicense or an option for a Sublicense. For
    the sake of clarity, Sublicensee shall include any other third party (other than a Subcontractor) to whom such rights shall
    be transferred or assigned, or who may assume control thereof by operation of law or otherwise.
	 	 	 
	 	1.4.21.	“Territory”
    shall mean Worldwide.
	 	 	 
	 	1.4.22.	“University”
    shall mean The Hebrew University of Jerusalem and each of its branches.

 

	2.	Reserved

 

	3.	The
    License

 

	3.1.	Subject
    to the full performance by the Company of its obligations in accordance with this Agreement, Yissum hereby grants the Company
    an exclusive license to make commercial use of the Licensed Technology, in order to develop, manufacture, market, distribute
    or sell a Product, all within the Field and the Territory only, subject to and in accordance with the terms and conditions
    of this Agreement (the “License”).
	 	 
	3.2.	Notwithstanding
    the provisions of Section 3.1, above, Yissum, on behalf of the University, shall retain the right (i) to make, use and practice
    the Licensed Technology for the University’s own research and educational purposes; (ii) to license or otherwise convey
    to other academic and not-for-profit research organizations, the Licensed Technology for use in non-commercial research; and
    (iii) to license or otherwise convey the Licensed Technology to any third party for research or commercial applications outside
    the Field.

 

	4.	Term
    of the License

 

The
License shall expire, if not earlier terminated pursuant to the provisions of this Agreement, on a country-by-country, Product-by-Product
basis, upon the later of: (i) the date of expiration in such country of the last to expire Licensed Patent included in the Licensed
Technology; (ii) the date of expiration of any exclusivity on the Product granted by a regulatory or government body in such country;
or (iii) the end of a period of twenty (20) years from the date of the First Commercial Sale in such country. Should the periods
referred to in Subsections (i) or (ii) expire in a particular country prior to the period referred to in Subsection (iii), above,
the license in that country or those countries shall be deemed a license to the Know-How during such post-expiration period.

 

Upon
the expiration of the later of the periods set forth in Subsections (i) through (iii) above (and provided that the License has
not been terminated prior thereto), the Company shall have a fully-paid non-exclusive license to the Know-How, and the Company
shall have an irrevocable option to obtain an exclusive license to the Know-How by agreeing to pay Yissum fifty percent (50%)
of the consideration set forth in Section 7.3 and 7.6 below, in respect of Net Sales and Sublicense Consideration received during
the period of such license which shall continue for a period of two (2) years after termination of the later of the periods as
referred to above and shall be renewed automatically for additional successive two (2) year periods, unless the Company or Yissum
notifies the other Party in writing prior to the end of the then current two (2) year period that it does not wish the license
to be renewed as aforesaid.

 

    	4

    	 

    

 

	5.	Development
    and Commercialization

 

	5.1.	The
    Company undertakes, at its own expense, to use its best efforts to carry out the development, regulatory, manufacturing and
    marketing work necessary to develop and commercialize Products in accordance with the Development Plan approved by Yissum,
    a copy of which is attached to this Agreement as Appendix B. The Development Plan may be modified from time to time
    by the Company as reasonably required in order to achieve the commercialization goals set forth above, upon Yissum’s
    prior written approval, but without derogating from the dates of the achievement of the Milestones set forth in this Section
    5. All terms and conditions of the License and this Agreement shall apply to the modified Development Plan and subsequent
    Development Results. Notwithstanding anything to the contrary contained herein, the Company undertakes to meet all of the
    following milestones (the “Development Milestones”) attached as Appendix B.
	 	 
	5.2.	The
    Company shall at the request of Yissum (i) provide Yissum with periodic written reports (“Development Reports”)
    not less than once per every twelve (12) months concerning all material activities undertaken in respect of the exercise of
    the License, (ii) keep Yissum informed on a timely basis concerning all material activities and changes to the Development
    Plan undertaken in respect of the exercise of the License, and (iii) at Yissum’s request, from time to time, provide
    Yissum with further information relating to the Company’s activities in exercise of the License. The Development Reports
    shall include detailed descriptions of the progress and results, if any, of: (a) the tests and trials conducted and all other
    actions taken by the Company pursuant to the Development Plan, and a summary of the Development Results and any other related
    work effected by the Company or by any Affiliate or Sublicensee during the twelve (12) months period prior to the report,
    (b) manufacturing, sublicensing, marketing and sales during the six (6) months period prior to the report; (c) the Company’s
    plans in respect of the testing, undertaking of trials or commercialization of Products for the following twelve (12) months;
    and (d) projections of sales and marketing efforts following the First Commercial Sale. Development Reports shall also set
    forth a general assessment regarding the achievement of any milestones; the projected – or actual – completion
    date of the development of a Product and the marketing thereof; as well as a description of any corporate transaction involving
    the Products or the Licensed Technology. If progress in respect of a Product differs from that anticipated in its Development
    Plan or a preceding Development Report, the Company shall explain, in its Development Report, the reason therefor and shall
    prepare a modified Development Plan for Yissum’s review and approval. The Company shall also make reasonable efforts
    to provide Yissum with any reasonable additional data that Yissum requires to evaluate the performance of the Company hereunder.
	 	 
	5.3.	The
    Company shall pursue the development and registration of all commercially reasonable indications or uses of the Licensed Technology
    in the Field.
	 	 
	5.4.	Upon
    completion of the development of any Product, the Company undertakes to perform all commercially reasonable actions necessary
    to maximize Net Sales of such Product on a regular and consistent basis. Payments of the License Maintenance Fee as set forth
    in Section ‎7 below, shall not release the Company from its obligation as stated in this Section.
	 	 
	5.5.	If
    the Company shall not meet the Development Milestones or shall not commercialize the Products within a reasonable time frame,
    unless such delay is caused by (i) the requirements of a regulatory or other governmental authority; (ii) force majeure in
    accordance with Section 17.9, below; or (iii) unless the Company and Yissum have agreed in writing to amend the Development
    Plan, Yissum shall notify the Company in writing of the Company’s failure to meet its obligations of diligence and shall
    allow the Company six(6) months to cure such failure of diligence. The Company’s failure to cure within such six (6)
    months period to Yissum’s reasonable satisfaction shall be a material breach of this Agreement, entitling Yissum to
    immediate termination under Section 15.2 below.
	 	 
	5.6.	The
    Company shall perform all its activities hereunder in accordance with all applicable laws and regulations, and shall procure
    the receipt of all approvals and consents necessary for the performance of its obligations hereunder.
	 	 
	5.7.	The
    Company agrees to provide Yissum and/or the University (for no consideration) a reasonable number of units of any Product
    developed and/or manufactured under this Agreement, for academic research purposes only.

 

    	5

    	 

    

 

	6.	Sublicenses

 

	6.1.	The
    Company shall only be entitled to grant a Sublicense after obtaining Yissum’s written approval regarding the identity
    of the Sublicensee and all material terms and conditions of the Sublicense, which approval shall not be unreasonably withheld
    or delayed. Notwithstanding the above, in case the Sublicensee is a company with annual turnover from sales of more than $250MM
    the approval of Yissum will not be required.
	 	 
	6.2.	Upon
    submission of its request to obtain the written consent of Yissum to a Sublicense, the Company shall fully disclose and submit
    to Yissum all documentation relating to the Sublicense, adequately disclose to Yissum any other business connection which
    it now has or is in the process of forming with the Sublicensee which may reasonably effect the decision of the Company regarding
    terms and conditions of the Sublicense; and shall notify Yissum in writing, whether a proposed Sublicensee is an Affiliate
    or is otherwise related to the Company. In addition, the Company shall provide Yissum with an executed copy of the Sublicense
    within ten (10) days of its execution. Any material amendments to a Sublicense shall be subject to Yissum’s prior written
    approval, and shall be subject to the Company providing Yissum with an executed copy of such amendment to the Sublicense within
    ten (10) days of the execution of such amendment.
	 	 
	6.3.	If
    the Company is unable or unwilling to serve or develop a potential market or market territory for which there is another party
    willing to be a Sublicensee, the Company shall, at Yissum’s request, negotiate in good faith a Sublicense with such
    party.
	 	 
	6.4.	Any
    Sublicense shall be dependent on the validity of the License and shall terminate upon termination of the License.
	 	 
	6.5.	The
    Company shall ensure that any Sublicense shall include material terms that require the Sublicensee to comply with the terms
    of this Agreement, including, Section 14 below, the breach of which terms shall be a material breach resulting in termination
    of the Sublicense. In such an event, the Company undertakes to take all reasonable steps to enforce such terms upon the Sublicensee,
    including the termination of the Sublicense. In all cases, the Company shall immediately notify Yissum of any breach of the
    material terms of a Sublicense, and shall copy Yissum on all correspondence with regard to such breach.
	 	 
	 	Furthermore,
    in the context of any Sublicense, the Company will obtain an agreement from the relevant Sublicensee (i) that such Sublicensee
    may only use the Licensed Technology and any related information received from the Company in connection with the further
    development and/or commercialization of a Product pursuant to the terms of the Sublicense agreement, and will keep same confidential;
    and (ii) naming Yissum as a third party beneficiary with the right to directly enforce the use and confidentiality provisions
    described in Subsection (i) above and the reporting provisions set out in Sections 6.6 and 8.2 below.
	 	 
	6.6.	Without
    derogating from the generality of Section 6.5 above, the Company shall require each Sublicensee to provide it with regular
    written royalty reports that include at least the detail that the Company is required to provide pursuant to Section 8.2 below.
    Upon request, the Company shall provide such reports to Yissum.
	 	 
	6.7.	Any
    act or omission of the Sublicensee which is not promptly remedied by the Company or the Sublicensee and which would have constituted
    a breach of this Agreement by the Company had it been an act or omission of the Company, and which the Company has not made
    best efforts to promptly cure, including termination of the Sublicense, shall constitute a breach of this Agreement by the
    Company.
	 	 
	6.8.	For
    the avoidance of any doubt it is hereby declared that under no circumstance whatsoever shall a Sublicensee be entitled to
    assign such Sublicense or further Sublicense the License or any part thereof.
	 	 
	6.9.	The
    Company shall not be entitled to grant any rights whatsoever in respect of the Licensed Technology or the Product to any third
    party, including rights of distribution/distributorship, except by means of a Sublicense.

 

    	6

    	 

    

 

	7.	License
    Consideration

 

In
consideration for the grant of the License, the Company shall pay Yissum the following consideration during the term of the License
as set forth in Section 4 above:

 

	7.1.	Royalties
    at a rate of Four percent (4%) of Net Sales (the “Royalties”).
	 	 
	7.2.	Sublicense
    fees at a rate of twenty percent (20%) of Sublicense Consideration.

 

	8.	Reports
    and Accounting

 

	8.1.	The
    Company shall give Yissum written notice of any (i) Sublicense Consideration received; (ii) or First Commercial Sale made/
	 	 
	8.2.	One
    (1) month after the end of each calendar quarter commencing from the earlier of (i) the First Commercial Sale; or (ii) the
    grant of a Sublicense or receipt of Sublicense Consideration, the Company shall furnish Yissum with a quarterly report (“Periodic
    Report”), certified as being correct by the chief financial officer of the Company, detailing the total sales and
    Net Sales effected during the preceding quarter, the total Sublicense Consideration received during the preceding quarter
    and the total Royalties and Sublicense Fees due to Yissum in respect of that period. Once the events set forth in Subsection
    (i) or (ii) above, have occurred, Periodic Reports shall be provided to Yissum whether or not Royalties and Sublicense Fees
    are payable for a particular calendar quarter. The Periodic Reports shall contain full particulars of all sales made by the
    Company, Affiliates or Sublicensees and of all Sublicense Consideration received, including a breakdown of the number and
    type of Products sold, discounts, returns, the country and currency in which the sales were made, invoice dates and all other
    data enabling the Royalties and Sublicense Fees payable to be calculated accurately.
	 	 
	8.3.	On
    the date prescribed for the submission of each Periodic Report, the Company shall pay the Royalties and Sublicense Fees due
    to Yissum for the reported period. All payments under this Agreement shall be computed and paid in US dollars, using the appropriate
    foreign exchange rate reported by the Bank of Israel on the last working day of the calendar quarter. Payment of value added
    tax or any other tax, charge or levy applicable to the payment to Yissum of the consideration as detailed in Section 7 above,
    shall be borne by the Company and added to each payment in accordance with the statutory rate in force at such time. All payments
    made to Yissum by an Israeli entity shall be made without the withholding of any taxes, provided that Yissum shall supply
    such Israeli entity, at its request, with a tax certificate indicating an official exemption from tax withholding for so long
    as Yissum has such a certificate. For the avoidance of doubt, if Yissum does not supply such certificate, the Israeli entity
    shall withhold taxes according to applicable law. All other payments to Yissum by non-Israeli entities shall be made without
    the withholding of any taxes. Payments may be made by check or by wire transfer to the following account:

 

Name
of Bank: Hapoalim

Bank
Key: 12

Bank’s
address: 1 Hamarpe Street, Jerusalem, Israel

Branch:
Jerusalem Business Branch - 436

Bank
account Number: 12-436-142-155001

Swift
Code: POALILIT

IBAN:
IL56-0124-3600-0000-0155-001 (for payment from Europe only)

 

	8.4.	The
    Company shall keep, and shall require its Affiliates and Sublicensees to keep, full and correct books of account in accordance
    with applicable Generally Accepted Accounting Principles as required by international accounting standards enabling the Royalties
    and Sublicense Fees to be calculated accurately. Starting from the first calendar year after the First Commercial Sale, or
    the first grant of a Sublicense, whichever occurs first, an annual report, authorized by a certified public accountant, shall
    be submitted to Yissum within ninety (90) days of the end of each calendar year, detailing Net Sales and Sublicense Consideration,
    Royalties and Sublicense Fees, both due and paid (the “Annual Reports”). The Annual Reports shall also
    include the Company’s sales and royalty forecasts for the following calendar year, if available.
	 	 
	 	The
    Company shall, and shall require and cause its Affiliates and Sublicensees to, retain such books of account for five (5) years
    after the end of each calendar year during the period of this Agreement, and, if this Agreement is terminated for any reason
    whatsoever, for five (5) years after the end of the calendar year in which such termination becomes effective.

 

    	7

    	 

    

 

	8.5.	Yissum
    will either (i) allow the Company a credit against future Royalties to be paid for Royalties previously paid on account of
    Net Sales, as appropriate, that were reported as bad debts in the Company’s annual audited financial statements; or
    (ii) if such bad debts are recorded by the Company in its annual audited financial statement after the Company’s obligation
    to pay Royalties has ceased, Yissum shall repay any Royalties received on account of Net Sales that were reported as bad debts
    by the Company.
	 	 
	8.6.	Yissum
    shall be entitled to appoint not more than two (2) representatives who must be independent certified public accountants or
    such other professionals as appropriate (the “Auditors”) to inspect during normal business hours the Company’s
    and its Affiliates’ books of account, records and other relevant documentation to the extent relevant or necessary for
    the sole purpose of verifying the performance of the Company’s payment obligations under this Agreement, the calculation
    of amounts due to Yissum under this Agreement and of all financial information provided in the Periodic Reports, provided
    that Yissum shall coordinate such inspection with the Company or Affiliate (as the case may be) in advance. In addition, Yissum
    may require that the Company, through the Auditors, inspect during normal business hours the books of account, records and
    other relevant documentation of any Sublicensees, to the extent relevant or necessary for the sole purpose of verifying the
    performance of the Company’s payment obligations under this Agreement, the calculation of amounts due to Yissum under
    this Agreement and of all financial information provided in the Periodic Reports, and the Company shall cause such inspection
    to be performed. The Parties shall reconcile any underpayment or overpayment within thirty (30) days after the Auditors deliver
    the results of the audit. Any underpayment shall be subject to interest in accordance with the terms of Section 8.7 below.
    In the event that any inspection as aforesaid reveals any underpayment by the Company to Yissum in respect of any year of
    the Agreement in an amount exceeding five percent (5%) of the amount actually paid by the Company to Yissum in respect of
    such year, then the Company shall, in addition, pay the cost of such inspection.
	 	 
	8.7.	Any
    sum of money due Yissum which is not duly paid on time shall bear interest from the due date of payment until the actual date
    of payment at the rate of annual LIBOR plus five percent (5%) per annum accumulated on a monthly basis.

 

	9.	Ownership

 

	9.1.	All
    right, title and interest in and to the Licensed Technology vest and shall vest solely in Yissum, and the Company shall hold
    and make use of the rights granted pursuant to the License solely in accordance with the terms of this Agreement.
	 	 
	9.2.	All
    rights in the Development Results shall be solely owned by the Company, except to the extent that an employee of the University,
    including, the Researcher, is considered an inventor of a patentable invention arising from the Development Results, in which
    case such invention and all patent applications and/or patents claiming such invention (“Joint Patents”)
    shall be owned jointly by the Company and Yissum, as appropriate.
	 	 
	9.3.	Upon
    the execution of this Agreement, the Company shall execute the letter of assignment attached to this Agreement as Appendix
    D concerning its interest in any Joint Patents that will provide that such interest will be irrevocably assigned to Yissum
    in the event that the Company is declared bankrupt, is voluntarily or involuntarily dissolved, or otherwise ceases operations.

 

    	8

    	 

    

 

	10.	Patents

 

	10.1.	Within
    ten (10) days of the Effective Date, the Company shall reimburse Yissum for all previous documented expenses and costs relating
    to the registration and maintenance of the Licensed Patents listed in Appendix A.
	 	 
	10.2.	Yissum,
    in consultation with the Company, shall be responsible for the filing, prosecution and maintenance of the Licensed Patents
    in the Territory, at the Company’s expense (the “Ongoing Patent Expenses”). Each application and
    every patent registration shall be made and registered in the name of Yissum or, should the law of the relevant jurisdiction
    so require, in the name of the relevant inventors and then assigned to Yissum. The Company agrees to have Yissum’s patent
    counsel directly bill the Company for such expenses and shall directly pay such bills in accordance with patent counsel’s
    directions.
	 	 
	10.3.	The
    Company undertakes and warrants that no amounts utilized by the Company for such payment of Ongoing Patent Expenses or for
    the reimbursement of Yissum’s past documented expenses and costs relating to the registration and maintenance of the
    Licensed Patents listed in Appendix A will be (i) funding provided by the Office of the Chief Scientist at the Israeli
    Ministry of Economics (the “OCS”); (ii) funding that is earmarked as supplementary funding (“mimun
    mashlim”) for an OCS approved project; or funding provided to the Company from any other governmental or regulatory
    institution of the State of Israel.
	 	 
	10.4.	Notwithstanding
    the foregoing in Section 10.2, above, upon the execution of this Agreement, the Company shall deposit with Yissum the amount
    of US$5000 to secure the payment of the Ongoing Patent Expenses (the “Expense Deposit”). Should the Company
    fail to pay any amounts due in connection with the Ongoing Patent Expenses within thirty (30) days following receipt of Yissum’s
    written request accompanied by a detailed account, Yissum shall be entitled pay the unpaid expenses from the Expense Deposit.
    In the event that Yissum utilizes some or all of the Expense Deposit as set forth in this Section, it shall so notify the
    Company in writing. The Company shall be obligated to deposit with Yissum an amount equal to the difference between US$5000
    and the balance in the Expense Deposit within thirty (30) days of its receipt of Yissum’s notice. Upon termination or
    expiration of this Agreement, Yissum shall return to the Company the nominal amount of any remaining Expense Deposit that
    will not be required to cover Ongoing Patent Expenses for the period up until such termination or expiration.
	 	 
	10.5.	Subject
    to the above, the Parties shall consult and make every effort to reach agreement in all respects relating to the manner of
    making applications for and registering the patents, including the time of making the applications, the countries where applications
    will be made and all other particulars relating to the registration and maintenance of the Licensed Patents. Notwithstanding
    the foregoing, Yissum reserves the sole right to make all final decisions with respect to the preparation, filing, prosecution
    and maintenance of such patent applications and patents.
	 	 
	10.6.	The
    Parties shall assist each other in all respects relating to the preparation of documents for the registration of any patent
    or any patent-related right upon the request of the other Party. Both Parties shall take all appropriate action in order to
    assist the other to extend the duration of a Licensed Patent or obtain any other extension obtainable under law, to maximize
    the scope of the protection afforded by the Licensed Patents.
	 	 
	10.7.	In
    the event that the Company is approached by a patent examiner or attorney in connection with any matter that is the subject
    matter of this Agreement, it shall give Yissum immediate notice of such approach. The Company shall only reply to such approaches
    after consultation with Yissum and subject to its consent.
	 	 
	10.8.	The
    Company, shall mark, and shall cause its Affiliates and Sublicensees to mark, all Products covered by one or more of the Licensed
    Patents with patent numbers (or the legend “patent pending”) applicable to such Product. The Company shall ensure
    that its Sublicensee complies with the provisions of this Section.

 

    	9

    	 

    

 

	10.9.	If
    at any time during the term of this Agreement the Company decides that it is undesirable, as to one or more countries, to
    file, prosecute or maintain any patents or patent applications within the Licensed Patents, it shall give at least ninety
    (90) days written notice thereof to Yissum, and upon the expiration of the ninety (90) day notice period (or such longer period
    specified in the Company’s notice) the Company shall be released from its obligations to bear the expenses to be incurred
    thereafter as to such patent(s) or patent application(s). As of such time, such patent(s) or application(s) shall be removed
    from the Licensed Technology and Yissum shall be free to grant rights in and to such patent(s) or patent application(s) in
    such countries to third parties, without further notice or obligation to the Company, and the Company shall have no rights
    whatsoever to exploit such patent(s) or patent application(s) or the Know-How related thereto. Notwithstanding the foregoing,
    the Company shall be required to bear the costs and expenses for filing, prosecuting and maintaining the Licensed Patents
    in at least the following jurisdictions: The United States, Canada, Japan, China, India, the United Kingdom, Germany, France,
    Italy, Israel and Spain (the “Required Jurisdictions”1). Should the Company fail to do so in
    the majority of the Required Jurisdictions, Yissum shall be entitled to terminate this Agreement after serving the Company
    with a 90 days advanced notice in which the Company has not cured the above breach, and without any need to compensate the
    Company in any manner.
	 	 
	10.10.	Other
    than in the Required Jurisdictions, in which Yissum shall file, prosecute diligently and maintain patents with the broadest
    protection obtainable, the foregoing does not constitute an obligation, representation or warranty, express or implied, on
    the part of Yissum that any patent or patent registration application will indeed be made or registered or be registerable
    in respect of the Licensed Technology or any part thereof, nor shall it constitute an obligation, representation, or warranty,
    express or implied, on the part of Yissum that a registered patent will be valid or afford any protection. For the avoidance
    of doubt, nothing in this Agreement constitutes an obligation, representation or warranty, express or implied, on the part
    of Yissum regarding the validity of or the protection afforded by any of the patents or patent registration applications detailed
    in Appendix A or regarding the commercial exploitability or any other value of the Licensed Technology or that the
    Licensed Technology will not infringe the rights of any third party.

 

	11.	Patent
    Rights Protection

 

	11.1.	The
    Company and Yissum shall each inform the other promptly in writing of any alleged infringements by a third party of the Licensed
    Patents in the Territory, together with any available written evidence of such alleged infringement.
	 	 
	11.2.	To
    the extent permitted by applicable law, if the Company, its Affiliate or any Sublicensee makes (directly or indirectly), any
    assertion, application or claim, or initiates or supports (directly or indirectly) any action or proceeding, that challenges
    the validity, enforceability or scope of any of the Licensed Patents (“Challenge
    Proceeding”), Yissum will have the right, at any time following the commencement of
    the Challenge Proceeding, to terminate this Agreement and the Royalty rates specified in this Agreement will be tripled with
    respect to Net Sales of Products that are sold, leased or otherwise transferred during the course of such Challenge Proceeding,
    and the percentage due to Yissum in respect of Sublicense Consideration will be tripled with respect to Sublicense Consideration
    during such period. If the outcome of such Challenge Proceeding is a determination in favor of Yissum, (a) the Royalty rate
    with respect to Net Sales of Products and the percentage due to Yissum with respect to Sublicense Consideration will remain
    at such triple rate as aforesaid; and (b) Company will reimburse Yissum for all expenses incurred by Yissum (including reasonable
    attorneys’ fees and court costs) in connection with such Challenge Proceeding. If the outcome of such Challenge Proceeding
    is a determination in favor of Company, Company will have no right to recoup any Royalties or Sublicense Fees paid before
    or during the course of such Challenge Proceeding.
	 	 
	11.3.	The
    Company, its Affiliate or Sublicensee shall have the first right in its own name and at its own expense to initiate any legal
    action and enforce the Licensed Patents against any infringement of such Licensed Patents. Before the Company, its Affiliate
    or its Sublicensee commences an action with respect to any infringement, the Company shall give careful consideration to the
    views of Yissum in making its decision whether or not to initiate any legal action and, if relevant, make these views known
    to its Affiliate or Sublicensee. The Company shall, or, if relevant, shall ensure that its Affiliate or Sublicensee shall,
    continuously keep Yissum apprised of all developments in the action and shall continuously provide Yissum with full information
    and copies of all documents relevant to the proceedings, including, all documents filed with the courts by the parties to
    the legal action(s) and all correspondence with the other parties to the proceedings, and shall seek Yissum’s input
    and approval on any substantive submissions or positions taken in the litigation regarding the scope, validity or enforceability
    of the Licensed Patents.

 

The
parties will discuss and agree on the final list of the Required Jurisdictions prior to signing the License Agreement.1

 

    	10

    	 

    

 

If
Yissum shall determine that the legal actions taken by the Company may adversely affect Yissum’s rights hereunder, Yissum
shall be entitled to appoint its own counsel to represent it in such litigation and the Company shall reimburse Yissum its actual
payments for such legal representation. If the Company, its Affiliate or its Sublicensee elects to commence an action as described
above and Yissum is a legally indispensable party to such action (being the registered owner of the infringed patent rights),
Yissum, at the Company’s expense, may be joined as a co-plaintiff, provided that all the following conditions shall be fulfilled:

 

(a)
the Company shall continuously provide Yissum with full information and copies of all documents relevant to the proceedings, including,
all documents filed with the courts by the parties to the legal action(s) and all correspondence with the other parties to the
proceedings, as well as all drafts of written submissions relating to such legal action that are sent to the Company for review,
and all Yissum’s comments in respect thereof will be taken into account;

 

(b)
any out of pocket expenses incurred by the Company or Yissum in connection with such action(s), including all legal and litigation
related fees and expenses, all out of pocket expenses for external assistance required to comply with any discovery or other motions
and any costs or amounts awarded to the counterparties in such action(s) shall be borne by the Company;

 

(c)
if Yissum shall determine that a conflict of interest exists between the Company and Yissum, Yissum shall be entitled, at its
own expense, to appoint its own counsel to represent it in such litigation and the Company shall make best efforts to ensure that
such counsel chosen by Yissum is fully informed and receives all material necessary to adequately participate in such action;
and

 

(d)
the Company shall bear all costs, expenses and awards incurred by or awarded against Yissum, with respect to any action filed
against Yissum alleging that an action initiated by the Company pursuant to the terms of this Section 11 was anticompetitive,
malicious, or otherwise brought for an improper purpose, whether by a counterparty to such aforementioned action or by any third
party.

 

If
Yissum is not required by law to be joined as a co-plaintiff, Yissum, to the extent permitted by law, and at its own cost, may
elect to join the action as a co-plaintiff at its own initiative and shall jointly control the action with the Company, its Affiliate
or its Sublicensee. Irrespective of whether Yissum joins any such action as described above it shall provide reasonable cooperation
to the Company, its Affiliate or its Sublicensee. The Company shall reimburse Yissum for any costs it incurs as part of an action
brought pursuant to this Section where Yissum has not elected to join the action as a co-plaintiff at its own initiative.

 

	11.4.	If
    the Company, its Affiliate or its Sublicensee does not bring an action against an alleged infringer pursuant to Section 11.3,
    above, or has not commenced negotiations with said infringer for discontinuance of said infringement within one hundred and
    eighty (180) days after learning of said infringement, Yissum shall have the right, but not the obligation, to bring an action
    for such infringement at its own expense, and retain all proceeds from such action. If the Company has commenced negotiations
    with said infringer for the discontinuance of said infringement within such one hundred and eighty (180) day period, the Company
    shall have an additional period of ninety (90) days from the end of the first one hundred and eighty (180) day period to conclude
    its negotiations before Yissum may bring an action for said infringement.
	 	 
	11.5.	No
    settlement, consent judgment or other voluntary disposition of an infringement suit may be entered without the consent of
    Yissum, which consent shall not be unreasonably withheld, conditioned or delayed. For the avoidance of doubt and notwithstanding
    anything to the contrary herein, should Yissum bring an action as set forth in Section 11.4 above, it shall have the right
    to settle such action by licensing the Licensed Technology, or part of it, to the alleged infringer.
	 	 
	11.6.	Any
    award or settlement payment resulting from an action initiated by the Company pursuant to this Section ‎11 shall be utilized,
    first to effect reimbursement of documented out-of-pocket expenses incurred by both Parties in relation to such legal action,
    and thereafter shall be paid to the Company and shall be deemed Sublicense Consideration received under this Agreement, in
    respect of which Sublicense Fees shall be due to Yissum.
	 	 
	11.7.	If
    either Party commences an action and then decides to abandon it, such Party will give timely notice to the other Party. The
    other Party may continue the prosecution of the suit after both Parties agree on the sharing of expenses.
	 	 
	11.8.	The
    Company shall use its best efforts at its own expense to defend any action, claim or demand made by any entity against the
    Company or Yissum in connection with rights in the Licensed Technology, and shall indemnify and hold harmless Yissum and the
    other Indemnitees (defined in Section 14.4 below) from and against all losses, damages and expenses arising in such regard.
    Each Party shall notify the other immediately upon learning of any such action, claim or demand as aforesaid.

 

    	11

    	 

    

 

	12.	Confidentiality

 

	12.1.	For
    the purposes of this Agreement (i) “Yissum Confidential Information” means this Agreement and the terms
    hereof and any and all reports, details, data, formulations, solutions, designs, and inventions and other information disclosed
    to the Company or any of its Representatives by Yissum or any of Yissum’s Representatives in connection with the Licensed
    Technology, Yissum, the University, the Researcher and other Representatives of Yissum and/or the University, whether in written,
    oral, electronic or any other form, except and to the extent that that any such information: (a) was known to the Company
    at the time it was disclosed, other than by previous disclosure by or on behalf of Yissum, as evidenced by the Company’s
    written records at the time of disclosure; (b) is in the public domain at the time of disclosure or becomes part of the public
    domain thereafter other than as a result of a violation by the Company or any of its Representatives of the confidentiality
    obligations herein; (c) is lawfully and in good faith made available to the Company by a third party who is not subject to
    obligations of confidentiality with respect to such information; or (d) is independently developed by the Company without
    the use of Yissum Confidential Information, as demonstrated by documentary evidence; and (ii) “Company Confidential
    Information” means this Agreement and the terms hereof and any and all reports, details, data, formulations, solutions,
    designs, and inventions and other information disclosed by or on behalf of the Company under this Agreement, whether in written,
    oral, electronic or any other form, except and to the extent that any such information: (a) was known to Yissum or the University
    at the time it was disclosed, other than by previous disclosure by or on behalf of the Company, as evidenced by Yissum’s
    or the University’s written records at the time of disclosure; (b) is in the public domain at the time of disclosure
    or becomes part of the public domain thereafter other than as a result of a violation by Yissum or its Representatives of
    the confidentiality obligations herein; (c) is lawfully and in good faith made available to Yissum or the University by a
    third party who is not subject to obligations of confidentiality with respect to such information; or (d) is independently
    developed by Yissum or the University without the use of the Company Confidential Information, as demonstrated by documentary
    evidence
	 	 
	12.2.	Yissum
    Confidential Information. The Company undertakes that during the term of this Agreement and for a period of five (5) years
    subsequent thereto, it shall maintain full and absolute confidentiality of and shall not use the Yissum Confidential Information
    other than for the purposes of this Agreement. The Company undertakes not to convey or disclose any of the Yissum Confidential
    Information to any third party without the prior written permission of Yissum. The Company shall be liable for its officers
    or employees or other Representatives maintaining absolute confidentiality of and not using or disclosing the Yissum Confidential
    Information except as expressly provided herein. The Company shall treat such Yissum Confidential Information with the same
    degree of care and confidentiality that it maintains or protect its own confidential information, but in any event, no less
    than a reasonable degree of care and confidentiality.
	 	 
	12.3.	Notwithstanding
    the foregoing, the Company may only disclose the Yissum Confidential Information:

 

	 	(a)	to
    those of its Representatives who have a “need to know” such information as necessary for the exercise of its rights
    and/or performance of its obligations hereunder, provided that such Representatives are legally bound by agreements which
    impose similar confidentiality and non-use obligations to those set out in this Agreement. The Company shall be responsible
    for ensuring that its Representatives abide by such undertakings of confidentiality; and
	 	 	 
	 	(b)	to
    any potential third party investor, including, any government, public foundation and/or private foundation, in connection
    with seeking potential funding for the Company, provided that such potential third party investor has executed a confidentiality
    and non-use agreement which imposes similar obligations to those set out in this Agreement; and
	 	 	 
	 	(c)	to
    any competent authority for the purposes of obtaining any approvals or permissions required for the exercise of the License
    and/or the implementation of this Agreement, or in the fulfillment of a legal duty owed to such competent authority (including
    a duty to make regulatory filings or to comply with any other reporting requirements); and

 

    	12

    	 

    

 

	 	(d)	to
    the extent required to be disclosed under any law, rule, regulation, court, or order of any competent authority, provided
    that the Company promptly notifies Yissum thereof in order to enable Yissum to seek an appropriate protective order or other
    reliable assurance that confidential treatment will be accorded to such information (with the Company’s assistance,
    if necessary), and such disclosure shall be made to the minimum extent required.

 

	12.4.	The
    Company Confidential Information. Yissum undertakes that during the term of this Agreement and for a period of five (5)
    years subsequent thereto, it shall maintain in confidence, and shall not use the Company Confidential Information other than
    for the purposes of this Agreement. Yissum undertakes not to convey or disclose any of the Company Confidential Information
    to any third party without the prior written permission of the Company. Yissum shall treat such Company Confidential Information
    with the same degree of care and confidentiality that each of them maintains and protects its own confidential information,
    but in any event, no less than a reasonable degree of care and confidentiality. Notwithstanding the foregoing, Yissum’s
    confidentiality obligations pursuant to this Section 12 to the extent relating to the Development Results shall terminate
    upon termination of this Agreement.
	 	 
	12.5.	Notwithstanding
    the foregoing, Yissum may only disclose the Company Confidential Information:

 

	 	(a)	to
    the University and to those of the Representatives of Yissum and/or the University who have a “need to know” such
    information as necessary for the exercise of Yissum’s rights and/or performance of Yissum’s obligations hereunder,
    provided that such Representatives are legally bound by agreements which impose similar confidentiality and non-use obligations
    to those set out in this Agreement; and
	 	 	 
	 	(b)	to
    any competent authority in connection with the filing and prosecution of patent applications relating to the Licensed Technology,
    or in the fulfillment of a legal duty owed to any competent authority; and
	 	 	 
	 	(c)	to
    the extent required to be disclosed under any law, rule, regulation, court, or order of any competent authority, provided
    that Yissum promptly notifies the Company thereof in order to enable the Company to seek an appropriate protective order or
    other reliable assurance that confidential treatment will be accorded to such information (with Yissum’s assistance,
    if necessary), and such disclosure shall be made to the minimum extent required.

 

	12.6.	The
    Company shall be responsible and liable to Yissum for any breach by its Representatives, Affiliates, Subcontractors, Sublicensees
    and investors of the undertakings of confidentiality set forth in this Section 12 as if such breach were a breach by the Company
    itself.
	 	 
	12.7.	Without
    prejudice to the foregoing, the Company shall not mention the name of the University, Yissum or the Researcher, unless required
    by law, in any manner or for any purpose in connection with this Agreement, the subject of the Research or any matter relating
    to the Licensed Technology, without obtaining the prior written consent of Yissum.
	 	 
	12.8.	Neither
    Party shall issue any press release or other media statement regarding the execution, existence or terms of this Agreement
    or any developments of the Licensed Technology without the prior written approval of the other Party.
	 	 
	12.9.	The
    provisions of this Section shall be subject to permitted publications pursuant to Section 13 below.

 

	13.	Publications

 

	13.1.	Yissum
    shall ensure that no publications in writing, in scientific journals or orally at scientific conventions relating to the Licensed
    Technology, the Development Plan, the Development Results or the Product, which are subject to the terms and conditions of
    this Agreement, are published by it or the Researcher, without first seeking the consent of the Company.
	 	 
	13.2.	The
    Company undertakes to reply to any such request for publication by Yissum within thirty (30) days of its receipt of a request
    in connection with the publication of articles in scientific journals, and within seven (7) days of its receipt of a request
    in connection with article abstracts. The Company may only decline such a request upon reasonable grounds, which shall be
    fully detailed in writing, requiring the postponement of such publication because it contains patentable subject matter for
    which patent protection should be sought, or the removal of any Company Confidential Information.

 

    	13

    	 

    

 

	13.3.	Should
    the Company decide to object to publication as provided in sub-Section 13.2, the publication shall be postponed for a period
    of not more than three (3) months from the date the publication was sent to the Company, to enable the filing of an appropriate
    patent application, or until the removal of the Company Confidential Information. Thereafter, the publication will automatically
    be permitted.
	 	 
	13.4.	The
    provisions of this Section 13 shall not prejudice any other right, which Yissum has pursuant to this Agreement or at law.
	 	 
	13.5.	For
    the avoidance of doubt, the prohibitions with respect to disclosure and publication set out in Sections 12 and 13 shall not
    apply to internal research and educational activities at the University for the Researcher and University employees provided
    that such persons are subject to written obligations of confidentiality substantially similar to those set forth in Section
    12.

 

	14.	Liability
    and Indemnity

 

	14.1.	TO
    THE EXTENT PERMITTED BY THE APPLICABLE LAW, YISSUM MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED,
    WITH RESPECT TO THE LICENSED TECHNOLOGY. IN PARTICULAR, YISSUM MAKES NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
    FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED TECHNOLOGY WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK
    OR OTHER RIGHTS OF ANY THIRD PARTY. IN ADDITION, NOTHING IN THIS AGREEMENT MAY BE DEEMED A REPRESENTATION OR WARRANTY BY YISSUM
    AS TO THE VALIDITY OF ANY OF THE LICENSED PATENTS OR THEIR REGISTRABILITY OR OF THE ACCURACY, SAFETY, EFFICACY, OR USEFULNESS,
    FOR ANY PURPOSE, OF THE LICENSED TECHNOLOGY. YISSUM HAS NO OBLIGATION, EXPRESS OR IMPLIED, TO SUPERVISE, MONITOR, REVIEW OR
    OTHERWISE ASSUME RESPONSIBILITY FOR THE PRODUCTION, MANUFACTURE, TESTING, MARKETING OR SALE OF ANY PRODUCT. TO THE EXTENT
    PERMITTED BY APPLICABLE LAW, NEITHER YISSUM NOR THE RESEARCHER, NOR THE UNIVERSITY, NOR THE REPRESENTATIVES OF YISSUM AND/OR
    OF THE UNIVERSITY SHALL HAVE ANY LIABILITY WHATSOEVER TO THE COMPANY OR TO ANY THIRD PARTY FOR OR ON ACCOUNT OF ANY INJURY,
    LOSS, OR DAMAGE, OF ANY KIND OR NATURE WHETHER DIRECT OR INDIRECT, SUSTAINED BY THE COMPANY OR BY ANY THIRD PARTY, FOR ANY
    DAMAGE ASSESSED OR ASSERTED AGAINST THE COMPANY, OR FOR ANY OTHER LIABILITY INCURRED BY OR IMPOSED UPON THE COMPANY OR ANY
    OTHER PERSON OR ENTITY, DIRECTLY OR INDIRECTLY ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM THIS AGREEMENT AND/OR
    THE EXERCISE OF THE LICENSE, INCLUDING, (i) THE PRODUCTION, MANUFACTURE, USE, PRACTICE, LEASE, OR SALE OF ANY PRODUCT; (ii)
    THE USE OF THE LICENSED TECHNOLOGY; OR (iii) ANY ADVERTISING OR OTHER PROMOTIONAL ACTIVITIES WITH RESPECT TO ANY OF THE FOREGOING.
	 	 
	14.2.	IN
    NO EVENT SHALL YISSUM, THE RESEARCHER, THE UNIVERSITY, OR THE REPRESENTATIVES OF YISSUM AND/OR OF THE UNIVERSITY BE LIABLE
    TO THE COMPANY OR ANY OF ITS AFFILIATES OR TO ANY THIRD PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE
    OR EXEMPLARY DAMAGES (INCLUDING, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY THE COMPANY OR ITS AFFILIATES
    OR ANY THIRD PARTY, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE OR TORT, OR OTHERWISE, ARISING
    OUT OF THIS AGREEMENT.
	 	 
	14.3.	The
    Company shall be liable for any loss, injury or damage whatsoever caused directly or indirectly to or suffered by its employees
    or any Representatives of Yissum or the University (including the Researcher and his/her team), or to any third party by reason
    of the Company’s acts or omissions pursuant to this Agreement or by reason of any use made by the Company, its Representatives,
    Affiliates, Subcontractors, and the Sublicensees and their respective business associates and customers of the Licensed Technology,
    the Development Results or any Product or exercise of the License.

 

    	14

    	 

    

 

	14.4.	The
    Company undertakes to compensate, indemnify, defend and hold harmless Yissum, the University, and any of their respective
    Representatives (including the Researcher and his/her team) (herein referred to jointly and severally as “Indemnitees”)
    from and against any claim, investigation or liability including, product liability, damage, loss, costs and expenses, including
    legal costs, attorneys’ fees and litigation expenses, incurred by or imposed upon the Indemnitees by reason of any acts
    or omissions of the Company, its Representatives, Affiliates, Subcontractors, and the Sublicensees, or which derive from the
    development, manufacture, marketing, sale, use or other exploitation, or sublicensing (as applicable) of any Product, or Licensed
    Technology, or the exercise of the License.
	 	 
	 	The
    Company shall ensure that its Sublicensees shall provide undertakings of indemnification which shall also be given also in
    favor of, and shall be actionable by Yissum, the University and any director, officer or employee of Yissum or of the University,
    and by the Researcher.
	 	 
	14.5.	As
    of the Effective Date, the Company shall procure and maintain, at its sole cost and expense, policies commensurate with industry
    standard of similar size and stage businesses. Such policy shall name the Indemnitees as additional insureds. The policy or
    policies so issued shall include a “cross-liability” provision pursuant to which the insurance is deemed to be
    separate insurance for each named insured (without right of subrogation as against any of the insured under the policy, or
    any of their representatives, employees, officers, directors or anyone in their name). Such comprehensive general liability
    insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage for the Company’s
    indemnification obligations under this Section 14. If the Company elects to self-insure all or part of the limits described
    above (including deductibles or retentions which are in excess of a $250,000 annual aggregate), such self-insurance program
    shall include assets or reserves which have been actuarially determined for the liabilities associated with this Agreement
    and must be reasonably acceptable to Yissum. /
	 	 
	 	The
    minimum amounts of insurance coverage required above shall not be construed to create a limit of the Company’s liability
    with respect to its indemnification obligations under this Section 14.
	 	 
	14.6.	The
    Company shall provide Yissum with written evidence of such insurance upon request. The Company shall provide Yissum with written
    notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. If the Company
    does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, Yissum shall have
    the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional
    waiting periods.
	 	 
	14.7.	The
    Company shall maintain, at its own expense, liability insurance as set forth in Section 14 above, beyond the expiration or
    termination of this Agreement as long as a Product relating to or developed pursuant to this Agreement is being commercially
    distributed or sold by the Company, an Affiliate or a Sublicensee, and thereafter as required by applicable laws.

 

	15.	Termination
    of the Agreement

 

	15.1.	Unless
    otherwise agreed by the Parties in writing, this Agreement shall terminate upon the occurrence of the later of the following:
    (i) the date of expiry of the last of the Licensed Patents anywhere in the Territory; (ii) the date of expiration of the last
    exclusivity on a Product granted by a regulatory or government body within the Territory; (iii) the expiry of a continuous
    period of twenty (20) years during which there shall not have been a First Commercial Sale of any Product in any country in
    the Territory; and (iv) if the Company elects to obtain an exclusive license to the Know-How pursuant to Section 4 above -
    the date of expiry of the period of such exclusive license.
	 	 
	15.2.	Without
    prejudice to the Parties’ rights pursuant to this Agreement or at law, either Party may terminate this Agreement by
    written notice to the other in any of the following cases:

 

	 	15.2.1.	immediately
    upon such written notice, if: (i) the other Party passes a resolution for voluntary winding up or a winding up application
    is made against it and not set aside within ninty (90) days; or (ii) a receiver or liquidator is appointed for the other Party;
    or (iii) the other Party enters into winding up or insolvency or bankruptcy proceedings. Each of the Parties undertakes to
    notify the other within seven (7) days if any of the abovementioned events occur; or

 

    	15

    	 

    

 

	 	15.2.2.	upon
    breach of this Agreement, where such breach has not been remedied within forty five (45) days from the breaching Party’s
    receipt of written notice from the non-breaching Party requiring such remedy.

 

	15.3.	In
    addition to the above, and without prejudice to Yissum’s rights pursuant to this Agreement or at law, Yissum shall be
    entitled to terminate this Agreement immediately upon written notice to the Company in the following circumstances:

 

	 	15.3.1.	non-performance
    or a delay of more than 6 months in the performance of the Development Plan;
	 	 	 
	 	15.3.2.	failure
    or a delay of more than six (6) months in meeting the Development Milestones as provided in Section 5 above;
	 	 	 
	 	15.3.3.	if
    an attachment is made over the Company’s assets or if execution proceedings are taken against the Company and the same
    are not set aside within sixty (60) days of the date the attachment is made or the execution proceedings are taken or the
    Company seeks protection under any laws or regulations, the effect of which is to suspend or impair the rights of any or all
    of its creditors, or to impose a moratorium on such creditors and such act is not cancelled within sixty (60) days of the
    performance thereof;
	 	 	 
	 	15.3.4.	uncured
    lapse of insurance coverage under Section 14 above;
	 	 	 
	 	15.3.5.	failure
    to defend against third party claims as required under Section ‎11 above;
	 	 	 
	 	15.3.6.	if
    the Company, its Affiliate or a Sublicensee initiates, supports or makes a Challenge Proceeding as detailed in Section 11.2
    above; or
	 	 	 
	 	15.3.7.	acts
    or omissions by the Company, or lack of sufficient funding, which indicate that the Company is not diligently developing or
    commercializing the Licensed Technology.

 

	15.4.	Upon
    termination of this Agreement for any reason other than the expiration of its term, the License shall terminate, the Licensed
    Technology and all rights included therein shall revert to Yissum, and Yissum shall be free to enter into agreements with
    any other third parties for the granting of a license or to deal in any other manner with such right as it shall see fit at
    its sole discretion.
	 	 
	 	The
    Company shall return or transfer to Yissum, within fourteen (14) days of termination of the License, all material, in soft
    or hard copy, relating to the Licensed Technology or Products connected with the License, and it may not make any further
    use thereof. In case of termination as set out herein, the Company will not be entitled to any reimbursement of any amount
    paid to Yissum under this Agreement. Yissum shall be entitled to conduct an audit in order to ascertain compliance with this
    provision and the Company agrees to allow access to Yissum or its representatives for this purpose.
	 	 
	15.5.	The
    Company will prepare and present all regulatory filings necessary or appropriate in any country and will obtain and maintain
    any regulatory approval required to market Products in any such country, at all its own expense. Company will solely own all
    right, title and interest in and to all such regulatory approvals and filings; provided, however, that (1) Company will provide
    copies thereof to Yissum on an on-going basis; and (2) without derogating from Company’s assignment undertaking in this
    Section 15.5 below, upon termination of the License (in whole or in part), Company agrees that Yissum shall have the right,
    on its own or via third parties, to reference, cross-reference, review, have access to, incorporate and use all documents
    and other materials filed by or on behalf of Company and its Affiliates with any regulatory authority in furtherance of applications
    for regulatory approval in the relevant country with respect to Products.

 

    	16

    	 

    

 

	 	Upon
    the termination of the Agreement for any reason other than the expiration of its term or due to an uncontested, uncured breach
    by Yissum (as set forth in Section 15.2.2 above), the Company shall transfer and assign to Yissum all of the Development Results
    and any information and documents, in whatever form, relating thereto, including any data, results, regulatory information
    (including applications, registrations, licenses, authorizations, approvals and all clinical studies, tests, and manufacturing
    batch records relating to a Product, and all data contained in any of the foregoing) and files that relate to the Licensed
    Technology or the Product(s) (collectively, the “Assigned Development Results”). The Company shall fully
    cooperate with Yissum to effect such transfer and assignment and shall execute any document and perform any acts required
    to do so.
	 	 
	 	Without
    derogating from the force and effect of the foregoing assignment undertaking, the Parties acknowledge and agree that if under
    applicable law the aforesaid assignment undertaking will not be fully enforceable, then the part (if any) of such undertaking
    which is enforceable shall remain in full force and effect, and the part (or whole) which is not enforceable shall be automatically
    replaced with an irrevocable grant by the Company to Yissum, binding upon all of the Company’s acquirers, successors
    and assignees, of an unrestricted, perpetual, irrevocable, worldwide, royalty-free, license to use, exploit, transfer and
    sublicense (on a multi-tier basis) the Assigned Development Results, for any and all purposes and uses. To the extent permitted
    by applicable law, such license will be exclusive.
	 	 
	 	Notwithstanding
    anything to the contrary in Section 11 (Confidentiality) or elsewhere in this Agreement, Yissum (on its own or via third parties)
    shall be entitled to freely exploit the Assigned Development Results without any obligation of confidentiality to the Company.
	 	 
	15.6.	Notwithstanding
    the foregoing, neither the termination of this Agreement for any reason nor the expiration of the License shall release the
    Company from its obligation to carry out any financial or other obligation which it was liable to perform prior to the Agreement’s
    termination or the License’s expiration. In the event that the Company terminates this Agreement, it shall be required
    to continue paying all Ongoing Patent Expenses for those Licensed Patents in existence on the date of notice of such termination,
    including expenses incurred by reason of examinations and extensions, for twelve (12) months following the effective date
    of such termination.
	 	 
	 	In
    addition, Sections 7, 8, 9, 12, 14, 15, 16 and 18 shall survive the termination of this Agreement to the extent required to
    effectuate the intent of the Parties as reflected in this Agreement.

 

	16.	Law

 

	16.1.	The
    provisions of this Agreement and everything concerning the relationship between the Parties in accordance with this Agreement
    shall be governed exclusively by Israeli law without application of any conflict of law principles that direct that the laws
    of another jurisdiction apply and jurisdiction shall be granted to the competent court in Jerusalem exclusively, except that
    Yissum may bring suit against the Company in any other jurisdiction outside the State of Israel in which the Company has assets
    or a place of business. The Company undertakes not to object to the enforcement against it of writs and decisions issued by
    any other jurisdiction outside the State of Israel under such circumstances. The Company hereby waives any immunity it may
    have against enforcement of any judgment so obtained against it by Yissum and waives any rights or claims that it may have
    with respect to forum non-conveniens.
	 	 
	16.2.	Each
    Party agrees that any breach or threatened breach of the terms and conditions of this Agreement governing confidentiality
    or the exploitation and use of the Licensed Technology may cause irreparable harm, that may be difficult to ascertain and
    that monetary damages may not afford an adequate remedy. Accordingly, in addition to all other rights and remedies that may
    be available to the non-breaching Party under this Agreement or by law, such Party shall be entitled to seek, in the courts
    and under the law mutually agreed to in Section 16.1 above, injunctive relief without proof of damages.

 

    	17

    	 

    

 

	17.	Miscellaneous

 

	17.1.	Relationship
    of the Parties. It is hereby agreed and declared between the Parties that they shall act in all respects relating to this
    Agreement as independent contractors and there neither is nor shall there be any employer-employee or principal-agent relationship
    or partnership relationship between the Company (or any of its employees) and Yissum. Each Party will be responsible for payment
    of all salaries and taxes and social welfare benefits and any other payments of any kind in respect of its employees and officers,
    regardless of the location of the performance of their duties, or the source of the directions for the performance thereof.
	 	 
	17.2.	Assignment.
    No Party may transfer or assign or endorse its rights, duties or obligations pursuant to this Agreement to another, without
    the prior written consent of the other Parties, which consent shall not be unreasonably denied, conditioned or delayed.
	 	 
	17.3.	No
    waiver. No waiver by any Party, whether express or implied, of its rights under any provision of this Agreement shall
    constitute a waiver of such Party’s rights under such provisions at any other time or a waiver of such Party’s
    rights under any other provision of this Agreement. The failure or delay of a Party to claim the performance of an obligation
    of another Party shall not be deemed a waiver of the performance of such obligation or of any future obligations of a similar
    nature.
	 	 
	17.4.	Representation
    by Legal Counsel. Each Party represents that it has been represented by legal counsel in connection with this Agreement
    and acknowledges that it has participated in drafting this Agreement. In interpreting and applying the terms and provisions
    of this Agreement, the Parties agree that no presumption shall exist or be implied against the Party which drafted such terms
    and provisions.
	 	 
	17.5.	Legal
    Costs. Each Party shall bear its own legal expenses involved in the negotiation and drafting of this Agreement.
	 	 
	17.6.	Disclosure
    of Agreements with Researcher. The Company shall disclose to Yissum any existing agreement or arrangement of any kind
    with the Researcher and or any representative of the Researcher, and shall not enter into any such agreement or arrangement
    without the prior written consent of Yissum.
	 	 
	17.7.	Taxes.
    Monetary amounts mentioned in this agreement do not include value added tax (“VAT”), or any duties or other
    taxes. Each Party shall itself be responsible to pay the taxes for which it is liable under the law.
	 	 
	17.8.	Severability.
    The provisions of this Agreement are severable and, in the event that any one or more of the provisions or part of a provision
    contained in this Agreement shall, for any reason, be held by any court of competent jurisdiction to be invalid, illegal or
    unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part
    of a provision of this Agreement; but such provision shall be modified as set out below and the balance of this Agreement
    shall be interpreted as if such provision were so modified. The Parties shall negotiate in good faith in order to agree on
    the terms of an alternative provision which complies with applicable law and achieves, to the greatest extent possible, the
    same effect as would have been achieved by the invalid, illegal or unenforceable provision. In the event that the Parties
    fail to agree within thirty (30) days, the head of the Israeli Bar Association (on his/her own or via a representative that
    he/she appoints) (“Deciding Expert”) will determine the text of the alternative provision, and each Party
    shall bear its own costs and the Parties shall equally bear the fees and expenses of the Deciding Expert. Each Party agrees
    that the determination of the Deciding Expert will be non-appealable, final and binding.
	 	 
	17.9.	Force
    Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or
    breached the Agreement for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for
    so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party
    and without fault of such Party, including fires, earthquakes, floods, embargoes, wars, acts of war (whether war is declared
    or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances (except of such Party’s
    personnel), acts of God or acts, omissions or delays in acting by any governmental authority provided that the nonperforming
    Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under
    this Agreement with reasonable dispatch whenever such causes are removed. The Party affected by such circumstances shall promptly
    notify the other Party in writing when such circumstances cause a delay or failure in performance and when they cease to do
    so.

 

    	18

    	 

    

 

	17.10.	Counterparts.
    This Agreement may be executed in any number of counterparts (including counterparts transmitted by facsimile and by electronic
    mail), each of which shall be deemed an original, but all of which taken together shall be deemed to constitute one and the
    same instrument.
	 	 
	17.11.	Binding
    Effect. This Agreement shall be binding upon the Parties once executed by both Parties and shall enter into force and
    become effective as of the later of the signature dates.
	 	 
	17.12.	Entire
    Agreement. This Agreement constitutes the full and complete agreement between the Parties and supersedes any and all agreements
    or understandings, whether written or oral, concerning the subject matter of this Agreement, and may only be amended by a
    document signed by both Parties.

 

	18.	Notices

 

All
notices and communications pursuant to this Agreement shall be made in writing and sent by facsimile, electronic mail or by registered
mail or served personally at the following addresses:

 

To
Yissum at:

 

Yissum
Research Development Company

of
The Hebrew University of Jerusalem Ltd.

P.O.
Box 39135,

Jerusalem
91390

Israel

Facsimile:
972-2-6586689

Email:
bob.trachtenberg@yissum.co.il

 

To
the Company at:

20
Raul Wallenberg,

Tel
-Aviv, Israel 6971916

Facsimile:
______________

Email:
______________

 

or
such other address furnished in writing by one Party to the other. Any notice served personally shall be deemed to have been received
on the day of service, any notice sent by registered mail as aforesaid shall be deemed to have been received seven (7) days after
being posted by prepaid registered mail. Any notice sent by facsimile or electronic mail shall be deemed to have been received
by the next business day after receipt of confirmation of transmission (provided that any notice terminating this Agreement which
is sent by electronic mail shall be followed by a notice sent in any other manner provided herein).

 

    	19

    	 

    

 

IN
WITNESS WHEREOF THE PARTIES HAVE SET THEIR HANDS

 

	YISSUM	 	THE
    COMPANY
	 	 	 	 	 
	By:	                           	 	By:	                          
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:	 

 

I
the undersigned, Prof. Shlomo Magdassi, have reviewed, am familiar with and agree to all of the above terms and conditions. I
hereby undertake to cooperate fully with Yissum in order to ensure its ability to fulfill its obligations hereunder, as set forth
herein.

 

	 	 	 
	Prof
    Shlomo Magdassi	 	Date
    signed

 

    	20

    	 

    

 

Appendix
A

 

LICENSED
PATENTS

 

KNOW-HOW

 

	YISSUM	 	THE
    COMPANY
	 	 	 	 	 
	By:	                        	 	By:	                          
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:	 

 

    	21

    	 

    

 

Appendix
B-1

 

THE
DEVELOPMENT PLAN

 

 

	YISSUM	 	THE
    COMPANY
	 	 	 	 	 
	By:	              	 	By:	                
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	Date:	 	 	Date:	 

 

    	22

    	 

    

 

Appendix
D

 

JOINT
PATENT ASSIGNMENT LETTER

 

ASSIGNMENT
AGREEMENT

Made
as a Deed

 

This
ASSIGNMENT AGREEMENT (the “Agreement”) is made this __ day of ______, 20__, by and between Yissum Research
Development Company of The Hebrew University of Jerusalem Ltd., Hi-Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel
on the one hand (“Yissum”) and Canna Powder ltd, of 20 Raul Walenberg, Tel-Aviv; on the other hand (the “Company”).
Yissum and the Company shall be referred each as a “Party”, and together as the “Parties”.

 

	WHEREAS,	on
    May 2, 2018, the Parties signed a Research Agreement and License Agreement (collectively, the “R&L Agreement”),
    according to which the Company received, among other things, a License to the Licensed Patents; and
	 	 
	WHEREAS,	pursuant
    to the R&L Agreement, certain inventions have been or shall/may be registered jointly in the name of Yissum and the Company
    and shall be regarded as Joint Patents; and
	 	 
	WHEREAS,	the
    Parties have agreed that, upon the occurrence of certain Events (as defined below), the Company shall assign and transfer
    to Yissum its title and ownership in and to the Joint Patents and thereafter Yissum shall become the sole and exclusive owner
    of such Joint Patents; all in accordance with the terms and conditions of this Agreement;

 

NOW
THEREFORE THE PARTIES DO HEREBY AGREE AS FOLLOWS:

 

	1.	Preamble

 

	 	1.1	The
    recitals hereto constitute an integral part hereof.
	 	 	 
	 	1.2	The
    headings of the sections in this Agreement are for the sake of convenience only and shall not serve in the interpretation
    of the Agreement.
	 	 	 
	 	1.3	All
    capitalized terms not defined herein shall have the meaning ascribed to such terms in the R&L Agreement.
	 	 	 
	 	1.4	In
    this Agreement the following expressions shall have the meanings appearing alongside them, unless the context otherwise requires:

 

“Effective
Date” shall mean the date of occurrence of the earliest of the Events.

 

“Event(s)”
shall mean a situation in which: (i) the Company passes a resolution for voluntary winding up or a winding up application
is made against it and not set aside within sixty (60) days; or (ii) a receiver or liquidator is appointed for the Company; or
(iii) the Company enters into winding up or insolvency or bankruptcy proceedings; or (iv) the Company ceases operations; or (v)
a Joint Patent has become a Relinquished Patent.

 

“Intellectual
Property Rights” shall mean any and all rights relating to intellectual property, including without limitation, all
inventions, patents and patent applications, including all re-issuances, continuations, continuations-in-part, divisions, revisions,
extensions and re-examinations thereof.

 

“Relinquished
Patent” shall mean a Joint Patent for which the Company fails to pay the expenses of the filing, prosecution, maintenance
or any activity required by the patent office, relating thereto.

 

	2.	Assignment
    of Joint Patents.

 

	 	2.1	Upon
    the Effective Date, the Company shall assign, convey and transfer to Yissum, its successors and assigns, the entire right,
    title and interest in and to any Joint Patent(s), including all Intellectual Property Rights therein, and all rights and benefits
    under any applicable law, treaty or convention. Notwithstanding the foregoing, in case the Event relates solely to a Relinquished
    Patent, the aforementioned assignment shall relate only to such Relinquished Patent.
	 	 	 
	 	2.2	Subsequent
    to an assignment pursuant to this Agreement, the Company or its successors, legal representatives or assigns shall notify
    Yissum, its successors, legal representatives and assigns, of any facts known to it regarding said Joint Patents, testify
    in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make
    all rightful oaths, and generally do everything possible to assist Yissum, its successors, legal representatives and assigns,
    to obtain and enforce proper protection, full ownership and rights of use for said Joint Patents in all countries.
	 	 	 
	 	2.3	In
    the event the Company, its successors, legal representatives or assigns fail to execute and deliver such documents and instruments
    promptly upon Yissum’s request, Yissum is hereby authorized and appointed attorney-in-fact of and for the Company to
    make, execute and deliver any and all such documents and instruments.

 

	3.	Governing
    Law and Jurisdiction. The provisions of this Agreement and everything concerning the relationship between the Parties
    in accordance with this Agreement shall be governed by the laws of the State of Israel and exclusive jurisdiction shall be
    granted to the appropriate courts in Jerusalem, Israel.
	 	 
	4.	Miscellaneous.
    This Agreement supersedes any prior understanding, agreement, practice or contract, oral or written, between the Parties with
    respect to the matters covered by this Agreement. This Agreement may not be modified except by written instrument signed by
    all Parties hereto. This Agreement may be executed in counterparts, each of which shall be deemed an original, but which together
    shall constitute one and the same instrument. This Agreement shall be binding upon the Parties’ heirs, executors, administrators,
    successors, and assigns. The invalidity of any provision of this Agreement shall not result in the invalidity of the entire
    Agreement.

 

AS
WITNESS THE HANDS OF THE PARTIES:

 

	Canna Powder Ltd,	 	Yissum Research Development Company
	20 Raul Wallenberg, Tel Aviv, Israel	 	of The Hebrew University of Jerusalem Ltd.
	 	 	 	Hi-Tech Park, Edmond J. Safra Campus,
		 	 	Givat Ram, P.O.B 39135, Jerusalem 91390, Israel
		 	 	 	 
	By:	                       	 	By:	                     
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 
	Date: 	 	 	Date:	 

 

    	23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]